Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.

  • 207 views
  • 23 Jan, 2021
  • 31 locations
Examination of Pirfenidone (Esbriet ) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

Examination of pirfenidone (Esbriet) therapy in coal workers' pneumoconiosis (black lung) with pulmonary fibrosis (scarring of the lung).

  • 0 views
  • 25 Jan, 2021
  • 1 location
Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects with dermatomyositis interstitial lung disease

  • 0 views
  • 23 Jan, 2021
  • 1 location
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis

-modifying therapies, pirfenidone and nintedanib, have been approved worldwide. Both drugs reduce the disease progression as measured by progressive decline in forced vital capacity (FVC), with a reduction

  • 0 views
  • 09 May, 2021
  • 1 location
A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.

nintedanib
diffusion capacity of the lung for carbon monoxide
idiopathic pulmonary fibrosis
pirfenidone
forced vital capacity
  • 384 views
  • 15 Feb, 2021
  • 132 locations
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

diffusion capacity of the lung for carbon monoxide
nintedanib
idiopathic pulmonary fibrosis
pirfenidone
carbon monoxide
  • 349 views
  • 02 Feb, 2021
  • 67 locations
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

diffusion capacity of the lung for carbon monoxide
nintedanib
idiopathic pulmonary fibrosis
pirfenidone
carbon monoxide
  • 0 views
  • 03 Feb, 2021
  • 10 locations
Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease

will use these measures to evaluate pirfenidone as a promising potential new treatment for patients with kidney disease.

cardiovascular disease
heart failure
nephropathy
renal failure
  • 0 views
  • 26 Jan, 2021
  • 2 locations
Treatment With Pirfenidone for COVID-19 Related Severe ARDS

A randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per nasogastric tube or orally as 801mg TID for 4 weeks in addition to Standard of Care (SoC), compared to SoC

  • 0 views
  • 27 Jan, 2021
  • 1 location
Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

-fibrotic therapies may offer an avenue to prevent progression of CLAD and prolong allograft survival. This study investigates if Pirfenidone therapy will stabilize lung function decline and slow

  • 1 views
  • 27 Jan, 2021
  • 1 location